AMRN

Amarin

• Reuters·8h ago

  BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron

• Reuters·10h ago

  BUZZ-U.S. STOCKS ON THE MOVE-Delta, Levi's, banks

• Reuters·11h ago

  Amarin says REDUCE-IT post hoc analysis shows Vascepa cuts events in highest-risk patients

• Reuters·12h ago

  AMERICAN COLLEGE OF CARDIOLOGY (ACC) SCIENTIFIC SESSIONS 2026 UNDERSCORE THE NEED FOR COMPLEMENTARY THERAPIES INCLUDING ICOSAPENT ETHYL (IPE) IN TREATMENT OF ELEVATED TRIGLYCERIDES AND CARDIOVASCULAR RISK REDUCTION

• TipRanks·03/27 22:27

  Amarin Streamlines Board, Updates Director Equity Compensation Plan

• Reuters·03/27 21:01

  Amarin board shrinks to seven directors; Paul Cohen and Oliver O'Connor exit ahead of 2026 annual meeting

• TipRanks·03/18 12:41

  Amarin highlights new recommendation for treatment of CV risk

• Benzinga·03/18 12:33

  Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia

• Reuters·03/18 12:32

  Amarin cites 2026 ACC/AHA dyslipidemia guideline support for icosapent ethyl in statin-treated patients with elevated triglycerides

• TipRanks·03/16 12:27

  Amarin to present data in patients at extreme cardiovascular risk

• Reuters·03/16 12:15

  Amarin to present new REDUCE-IT subgroup analysis of icosapent ethyl at ACC 2026

• TipRanks·03/04 06:01

  Amarin’s European Outlook Hinges on Recordati’s VAZKEPA Execution, Raising Commercial and IP Risk

• TipRanks·03/03 00:20

  Amarin Earnings Call: Cost Cuts, Cash, and Crosswinds

• TipRanks·03/02 13:26

  Amarin highlights recent data published on REDUCE-IT study

• Benzinga·03/02 13:16

  Amarin Published Data In The European Journal Of Preventive Cardiology Showing That VASCEPA Was Associated With Fewer Hospitalizations In A REDUCE-IT Analysis